Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.asjsur.2021.02.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II).
Sci Rep
November 2024
Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yada, Suruga-ku, Shizuoka, Shizuoka, 422-8002, Japan.
Article Synopsis
- Dexamethasone, commonly used to prevent nausea from chemotherapy, has side effects that prompt the search for alternatives without it.
- This study tested the efficacy and safety of palonosetron, aprepitant, and olanzapine in chemotherapy-naïve breast cancer patients, assessing their effectiveness in controlling nausea and vomiting.
- Results showed low total control rates (17.1%) for antiemetic therapies excluding dexamethasone, though olanzapine could be a viable replacement for patients unable to use dexamethasone.
Prevalence of anticipatory nausea and vomiting in breast cancer patients undergoing highly emetogenic chemotherapy.
Rev Assoc Med Bras (1992)
May 2024
Faculty of Medicine of ABC, Brazilian Institute for Cancer Control - Santo André (SP), Brazil.
Objective: Anticipatory nausea and vomiting are unpleasant symptoms observed before undergoing chemotherapy sessions. Less is known about the occurrence of symptoms since the advent of the new neurokinin-1 antagonist.
Methods: This prospective cohort study was performed at a single Brazilian Institution.
Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal.
Curr Oncol
January 2023
Departamento de Ciências Biomédicas e Medicina, Universidade do Algarve, 8005-139 Faro, Portugal.
Chemotherapy-induced nausea and vomiting (CINV) negatively impact cancer patients' quality of life and treatment outcomes. This study evaluated the achievement of complete response to CINV prophylaxis during the first five days after chemotherapy in adult outpatient cancer clinics with solid malignant tumours receiving Moderate or Highly Emetogenic Chemotherapy (MEC or HEC) in Portugal. During the study, patients completed three evaluations, and nausea severity and CINV impact on patients' daily life was assessed.
View Article and Find Full Text PDFCost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective.
Support Care Cancer
November 2022
Genolier Cancer Centre, Clinique de Genolier, Genolier, Switzerland.
Purpose: The aim of this study was to assess the cost-effectiveness of NEPA, a fixed-dose combination of oral netupitant (300 mg) and palonosetron (0.5 mg), compared to available treatments in Spain after aprepitant generic introduction in the market, and to discuss results in previously performed analyses in different wordwide settings.
Methods: A Markov model including three health states, complete protection, complete response at best and incomplete response, was used to evaluate the cost-effectiveness of NEPA versus common treatment options in Spain during 5 days after chemotherapy.
Avoiding emetogenic anesthetics and using prophylactic antiemetics for patients with high risk of postoperative nausea and vomiting.
Asian J Surg
May 2021
Department of Anesthesiology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!